ADMP Announces Positive Results For Its Dry Powder Inhaler Product; BOTA Commences Dosing In Vapendavir Phase 2b Trial
March 04, 2015 at 05:15 AM EST
ADMP announced the results of its pharmacokinetic (PK) study for its dry powder inhaler product, APC-5000. BOTA announced it has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir.